Indoco Remedies Limited (INDOCO.BO)
INR 235.05
(0.45%)
INR 235.05
(0.45%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 1.29 Billion INR | -20.42% |
| 2022 | 1.91 Billion INR | -11.0% |
| 2021 | 2.15 Billion INR | 66.27% |
| 2020 | 1.29 Billion INR | 328.36% |
| 2019 | 302.19 Million INR | 251.05% |
| 2018 | -200.06 Million INR | -145.87% |
| 2017 | 436.14 Million INR | -36.29% |
| 2016 | 684.62 Million INR | -25.46% |
| 2015 | 918.41 Million INR | -23.31% |
| 2014 | 1.19 Billion INR | 46.47% |
| 2013 | 817.67 Million INR | 16.93% |
| 2012 | 699.27 Million INR | 5.85% |
| 2011 | 660.61 Million INR | 14.76% |
| 2010 | 575.66 Million INR | 25.05% |
| 2009 | 460.33 Million INR | -29.42% |
| 2008 | 652.22 Million INR | 0.0% |
| 2007 | - INR | -100.0% |
| 2006 | 532.91 Million INR | -3.23% |
| 2005 | 550.68 Million INR | 23.08% |
| 2004 | 447.4 Million INR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 202.5 Million INR | -10.56% |
| 2024 Q2 | 114.3 Million INR | -43.56% |
| 2023 Q2 | 499.6 Million INR | 21.0% |
| 2023 Q1 | 412.9 Million INR | -13.37% |
| 2023 FY | 1.52 Billion INR | -20.42% |
| 2023 Q4 | 226.4 Million INR | -41.27% |
| 2023 Q3 | 385.5 Million INR | -22.84% |
| 2022 FY | 1.91 Billion INR | -11.0% |
| 2022 Q1 | 513.5 Million INR | -17.83% |
| 2022 Q2 | 722 Million INR | 40.6% |
| 2022 Q3 | 448.7 Million INR | -37.85% |
| 2022 Q4 | 476.6 Million INR | 6.22% |
| 2021 Q2 | 669.9 Million INR | 3.59% |
| 2021 Q1 | 646.7 Million INR | 75.12% |
| 2021 FY | 2.15 Billion INR | 66.27% |
| 2021 Q3 | 542.3 Million INR | -19.05% |
| 2021 Q4 | 624.9 Million INR | 15.23% |
| 2020 FY | 1.29 Billion INR | 328.36% |
| 2020 Q1 | 297.8 Million INR | 155.94% |
| 2020 Q4 | 369.28 Million INR | -15.42% |
| 2020 Q3 | 436.6 Million INR | 2.32% |
| 2020 Q2 | 426.7 Million INR | 43.28% |
| 2019 FY | 302.19 Million INR | 251.05% |
| 2019 Q3 | 180 Million INR | 18.66% |
| 2019 Q1 | 60.6 Million INR | -54.4% |
| 2019 Q4 | 116.35 Million INR | -35.36% |
| 2019 Q2 | 151.7 Million INR | 150.33% |
| 2018 Q3 | 75.6 Million INR | 246.23% |
| 2018 Q1 | -50.1 Million INR | 0.0% |
| 2018 FY | -200.06 Million INR | -145.87% |
| 2018 Q4 | 132.89 Million INR | 75.79% |
| 2018 Q2 | -51.7 Million INR | -3.19% |
| 2017 FY | 436.14 Million INR | -36.29% |
| 2016 FY | 684.62 Million INR | -25.46% |
| 2015 FY | 918.41 Million INR | -23.31% |
| 2014 Q1 | 277.2 Million INR | 0.0% |
| 2014 FY | 1.19 Billion INR | 46.47% |
| 2013 Q1 | 172.1 Million INR | -14.28% |
| 2013 FY | 817.67 Million INR | 16.93% |
| 2012 Q4 | 200.77 Million INR | 0.0% |
| 2012 FY | 699.27 Million INR | 5.85% |
| 2011 FY | 660.61 Million INR | 14.76% |
| 2010 FY | 575.66 Million INR | 25.05% |
| 2009 FY | 460.33 Million INR | -29.42% |
| 2008 FY | 652.22 Million INR | 0.0% |
| 2007 FY | - INR | -100.0% |
| 2006 FY | 532.91 Million INR | -3.23% |
| 2005 FY | 550.68 Million INR | 23.08% |
| 2004 FY | 447.4 Million INR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 5.75 Billion INR | 77.553% |
| Aurobindo Pharma Limited | 42.2 Billion INR | 96.937% |
| Glenmark Life Sciences Limited | 8.97 Billion INR | 85.605% |
| Granules India Limited | 6.81 Billion INR | 81.039% |
| Achyut Healthcare Limited | 4.43 Million INR | -29024.583% |
| Ajanta Pharma Limited | 19.67 Billion INR | 93.431% |
| Alkem Laboratories Limited | 19.46 Billion INR | 93.359% |
| Alpa Laboratories Limited | 184.49 Million INR | -600.58% |
| Brooks Laboratories Limited | 14.44 Million INR | -8851.17% |
| AstraZeneca Pharma India Limited | 1.71 Billion INR | 24.742% |
| Bajaj HealthCare Limited | - INR | -Infinity% |
| Bliss GVS Pharma Limited | 1.23 Billion INR | -5.0% |
| Dr. Reddy's Laboratories Limited | 67.72 Billion INR | 98.092% |
| Eris Lifesciences Limited | 5.18 Billion INR | 75.056% |
| FDC Limited | 2.98 Billion INR | 56.716% |
| Glenmark Pharmaceuticals Limited | 6.5 Billion INR | 80.122% |
| Gufic Biosciences Limited | 1.32 Billion INR | 2.809% |
| Ind-Swift Laboratories Limited | 4.42 Billion INR | 70.76% |
| Ipca Laboratories Limited | 7.98 Billion INR | 83.804% |
| Jagsonpal Pharmaceuticals Limited | 508.13 Million INR | -154.374% |
| Krebs Biochemicals & Industries Limited | -151.95 Million INR | 950.602% |
| Lasa Supergenerics Limited | -458 Million INR | 382.213% |
| Laurus Labs Limited | 3.94 Billion INR | 67.266% |
| Lupin Limited | 28.04 Billion INR | 95.391% |
| Mankind Pharma Limited | 21.51 Billion INR | 93.993% |
| Medicamen Biotech Limited | - INR | -Infinity% |
| Medico Remedies Limited | 100.3 Million INR | -1188.683% |
| Megasoft Limited | -121.1 Million INR | 1167.305% |
| NATCO Pharma Limited | 25.96 Billion INR | 95.021% |
| Piramal Pharma Limited | 4.55 Billion INR | 71.635% |
| RPG Life Sciences Limited | 2.29 Billion INR | 43.613% |
| Sigachi Industries Limited | 1.47 Billion INR | 12.304% |
| Sun Pharmaceutical Industries Limited | 104.3 Billion INR | 98.761% |
| Suven Pharmaceuticals Limited | 4.6 Billion INR | 71.948% |
| Syncom Formulations (India) Limited | 249.25 Million INR | -418.573% |
| Unichem Laboratories Limited | - INR | -Infinity% |
| Wanbury Limited | 569.71 Million INR | -126.876% |
| Windlas Biotech Limited | 1.29 Billion INR | 0.488% |
| ZIM Laboratories Limited | 253.82 Million INR | -409.22% |
| Zydus Lifesciences Limited | 43.1 Billion INR | 97.002% |
| Sun Pharma Advanced Research Company Limited | -4.11 Billion INR | 131.41% |
| Divi's Laboratories Limited | 33.08 Billion INR | 96.093% |
| Hester Biosciences Limited | 364.81 Million INR | -254.307% |
| Procter & Gamble Health Limited | 2.78 Billion INR | 53.606% |
| Amrutanjan Health Care Limited | 457.54 Million INR | -182.497% |
| Bal Pharma Limited | 233.9 Million INR | -452.586% |
| Strides Pharma Science Limited | 5.22 Billion INR | 75.266% |
| Venus Remedies Limited | 534.65 Million INR | -141.756% |
| Aarti Pharmalabs Limited | 3.12 Billion INR | 58.68% |
| Nectar Lifesciences Limited | 923.8 Million INR | -39.916% |
| Shilpa Medicare Limited | 1.36 Billion INR | 5.396% |
| Aarti Drugs Limited | 7.14 Billion INR | 81.919% |
| IOL Chemicals and Pharmaceuticals Limited | 1.59 Billion INR | 19.054% |
| Suven Life Sciences Limited | -1.22 Billion INR | 205.443% |
| Ind-Swift Limited | 1.22 Billion INR | -5.431% |
| Valiant Laboratories Limited | - INR | -Infinity% |
| J. B. Chemicals & Pharmaceuticals Limited | 14.28 Billion INR | 90.95% |
| Solara Active Pharma Sciences Limited | -3.85 Billion INR | 133.547% |
| Themis Medicare Limited | 392.58 Million INR | -229.237% |
| Hikal Limited | 32.11 Million INR | -3925.378% |
| Torrent Pharmaceuticals Limited | 25.33 Billion INR | 94.898% |
| Sequent Scientific Limited | - INR | -Infinity% |
| Novartis India Limited | 626.5 Million INR | -106.313% |
| Wockhardt Limited | -670 Million INR | 292.918% |
| Jubilant Pharmova Limited | 5.18 Billion INR | 75.091% |
| Biofil Chemicals and Pharmaceuticals Limited | 9.06 Million INR | -14152.859% |
| Neuland Laboratories Limited | 5.31 Billion INR | 75.695% |
| Morepen Laboratories Limited | 4.17 Billion INR | 69.032% |
| Kilitch Drugs (India) Limited | 208.05 Million INR | -521.268% |
| Mangalam Drugs & Organics Limited | 27.45 Million INR | -4607.368% |